Post-Marketing Progress: Drug Industry Is Meeting Phase IV Commitments, FDA Says
This article was originally published in RPM Report
Executive Summary
FDA’s John Jenkins disputes accusations that the pharmaceutical industry does not take post-marketing studies seriously and that the agency is lax on enforcement. According to updated data from FDA, Phase IV studies are being completed in a timely manner, Jenkins argues – and when they aren’t, the agency is taking action.